News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Subscribe To Our Newsletter & Stay Updated
